AMLX vs. KRRO, ACIU, ERAS, VERV, ALXO, LXRX, ESPR, SLRN, TBPH, and PGEN
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Korro Bio (KRRO), AC Immune (ACIU), Erasca (ERAS), Verve Therapeutics (VERV), ALX Oncology (ALXO), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Theravance Biopharma (TBPH), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Amylyx Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500.
Korro Bio has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of 4.14% beat Korro Bio's return on equity.
Amylyx Pharmaceuticals received 13 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 62.50% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals currently has a consensus price target of $28.67, indicating a potential upside of 1,519.59%. Korro Bio has a consensus price target of $122.50, indicating a potential upside of 164.01%. Given Amylyx Pharmaceuticals' higher possible upside, research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Korro Bio.
Amylyx Pharmaceuticals has higher revenue and earnings than Korro Bio.
In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Korro Bio. MarketBeat recorded 4 mentions for Amylyx Pharmaceuticals and 0 mentions for Korro Bio. Amylyx Pharmaceuticals' average media sentiment score of 0.73 beat Korro Bio's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Amylyx Pharmaceuticals beats Korro Bio on 9 of the 16 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
